miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial - Concepedia

Concepedia

Publication | Open Access

miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial

DOI Full Paper Access

45

Citations

32

References

2019

Year

Gayathri Anandappa, Andrea Lampis, David Cunningham, Khurum Khan, Kyriakos Kouvelakis, Georgios Vlachogiannis, Somaieh Hedayat, Nina Tunariu, Sheela Rao, David Watkins,

Clinical Cancer Research

Abstract

Our study validates the role of miR-31-3p as potential predictive biomarker of selection for anti-EGFR mAbs.

References

	Year	Citations

Page 1